Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pazopanib extended PFS in patients with carcinoid tumors

Publish date:: June 5, 2019

Key clinical point: Pazopanib improved progression-free survival versus placebo in patients with progressive carcinoid tumors, though toxicities were higher.

Major finding: Median PFS was 11.6 months for patients receiving the small molecule VEGF inhibitor, versus 8.5 months for those receiving placebo (P = .0005).

Study details: Alliance A021202, a prospective randomized trial of 161 patients with progressive carcinoid tumors.

Disclosures: Dr. Bergsland reported disclosures related to More Health, UpToDate, Advanced Accelerator Applications, Lexicon, Merck, and Novartis.

Citation:

Bergsland EK et al. ASCO 2019, Abstract 4005.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,